The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1656
ISSUE1656
August 8, 2022
Lumateperone (Caplyta) for Bipolar Depression
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Lumateperone (Caplyta) for Bipolar Depression
August 8, 2022 (Issue: 1656)
The oral second-generation antipsychotic drug
lumateperone (Caplyta – Intra-Cellular Therapies),
which was approved by the FDA in 2020 for treatment
of schizophrenia, is now approved for use as
monotherapy or as an adjunct to lithium or...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.